Mostrar el registro sencillo

dc.contributor.authorGonzález González, Alberto
dc.contributor.authorGarcía Sánchez, Daniel
dc.contributor.authorDotta, Monica
dc.contributor.authorRodríguez Rey, José Carlos 
dc.contributor.authorPérez Campo, Flor María 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2021-04-14T18:06:27Z
dc.date.available2021-04-14T18:06:27Z
dc.date.issued2020-12
dc.identifier.issn1948-0210
dc.identifier.otherRTI2018-097324es_ES
dc.identifier.urihttp://hdl.handle.net/10902/21224
dc.description.abstractMesenchymal stem cells (MSCs) are the most frequently used stem cells in clinical trials due to their easy isolation from various adult tissues, their ability of homing to injury sites and their potential to differentiate into multiple cell types. However, the realization that the beneficial effect of MSCs relies mainly on their paracrine action, rather than on their engraftment in the recipient tissue and subsequent differentiation, has opened the way to cell-free therapeutic strategies in regenerative medicine. All the soluble factors and vesicles secreted by MSCs are commonly known as secretome. MSCs secretome has a key role in cell-to-cell communication and has been proven to be an active mediator of immune-modulation and regeneration both in vitro and in vivo. Moreover, the use of secretome has key advantages over cell-based therapies, such as a lower immunogenicity and easy production, handling and storage. Importantly, MSCs can be modulated to alter their secretome composition to better suit specific therapeutic goals, thus, opening a large number of possibilities. Altogether these advantages now place MSCs secretome at the center of an important number of investigations in different clinical contexts, enabling rapid scientific progress in this field.es_ES
dc.description.sponsorshipSupported by Spanish Ministerio de Economía y competitividad, No. RTI2018-097324; Predoctoral program in Biomedicine from the University of Cantabria and the Instituto de Investigación Valdecilla (IDIVAL), No. PREVAL 19/02 and PREVAL 20/01.es_ES
dc.format.extent24 p.es_ES
dc.language.isoenges_ES
dc.publisherBaishideng Publishing Groupes_ES
dc.rightsCreative Commons Attribution NonCommercial (CC BY-NC 4.0) license. ©The Author(s).Published by Baishideng Publishing Group Inc.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceWorld J Stem Cells . 2020 Dec 26;12(12):1529-1552es_ES
dc.subject.otherMesenchymal Stem Cellses_ES
dc.subject.otherSecretomees_ES
dc.subject.otherSoluble Factorses_ES
dc.subject.otherExtra-Cellular Vesicleses_ES
dc.subject.otherExosomeses_ES
dc.subject.otherBone Regenerationes_ES
dc.titleMesenchymal stem cells secretome : The cornerstone of cell-free regenerative medicinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://dx.doi.org/10.4252/wjsc.v12.i12.0000es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.4252/wjsc.v12.i12.0000
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license. ©The Author(s).Published by Baishideng Publishing Group Inc.Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license. ©The Author(s).Published by Baishideng Publishing Group Inc.